Shares of Anthem BioSciences rose after Citi initiated coverage with a Buy rating and a target price of ₹870, implying over 20% upside. Ana...

The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pe...

Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by...

Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...

Affordable semaglutide generics are coming to India. This drug helps with diabetes and weight loss. Millions need it for health issues. How...

Mankind Pharma is set to enter India's semaglutide market soon. The drug's patent expires this month, opening doors for new players. Mankin...

Novo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide ...

Semaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic d...

Biocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...

Shares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco...

Eris Lifesciences has partnered with Natco Pharma to introduce semaglutide in the Indian market a cutting-edge therapy for Type 2 diabetes ...

Emcure Pharmaceuticals has launched Poviztra, a semaglutide injection for weight loss, becoming the first Indian company to exclusively dis...

In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the compan...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...

Biocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 Ind...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027. This strategic ...

Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It targets both d...